TY - JOUR AU - Rennard, Stephen I. AU - Calverley, Peter MA AU - Goehring, Udo M. AU - Bredenbröker, Dirk AU - Martinez, Fernando J. PY - 2011 DA - 2011/12/01 TI - Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD JO - Respiratory Research SP - 18 VL - 12 IS - 1 AB - As chronic obstructive pulmonary disease (COPD) is a heterogeneous disease it is unlikely that all patients will benefit equally from a given therapy. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, has been shown to improve lung function in moderate and severe COPD but its effect on exacerbations in unselected populations was inconclusive. This led to the question of whether a responsive subset existed that could be investigated further. SN - 1465-993X UR - https://doi.org/10.1186/1465-9921-12-18 DO - 10.1186/1465-9921-12-18 ID - Rennard2011 ER -